

MATERIALS LICENSE
SUPPLEMENTARY SHEET

47-17745-01

License or Reference number

Amendment No. 13

St. Francis Hospital
519 Donnally Street
Charleston, West Virginia 25301

Docket #
30-13268

In accordance with application dated June 5, 1984, License Number 47-17745-01 is amended as follows:

Conditions 12. and 17. are amended to read:

12. Licensed material listed in Item 6 above is authorized for use by, or under the supervision of, the following individual(s) for the materials and uses indicated:

W. Alva Deardorff, M.D.

Groups I through V

Paul Francke, M.D.

Groups I through V

Thomas M. Hayes, M.D.

Groups I, II and III

Iodine 131 for treatment of hyperthyroidism, cardiac dysfunction, and thyroid carcinoma
Phosphorus 32 as colloidal chromic phosphate for intracavitary treatment of malignant effusions

Martin S. Wershba, M.D.

Groups I, II and III

Iodine 131 for treatment of hyperthyroidism, cardiac dysfunction and thyroid carcinoma

Carl R. Duncan, M.D.

Groups I, II and III

Ravindra K. Gogineni, M.D.

Groups I, II and III

Iodine 131 as iodine for thyroid uptake studies, and for treatment of hyperthyroidism and cardiac dysfunction

Alan R. Nichols

Groups I, II and III

Carl B. Binns, M.D.

Groups I, II and III

Phosphorus 32 as colloidal
Chromic phosphate for intracavitary treatment of malignant effusions

8510310226 840823
REG2 LIC30
47-17745-01 PDR

7112041

NUCLEAR LICENSE
SUPPLEMENTARY SHEET

(cont'd)

CONDITIONS

17. Except as specifically provided otherwise by this license, the licensee shall possess and use licensed material described in Items 6, 7, and 8 of this license in accordance with statements, representations, and procedures contained in letters dated September 16, 1977, November 23, 1977, December 5, 1977, January 12, 1978, April 10, 1980, March 22, 1982, June 25, 1982, and January 17, 1983; application dated January 18, 1983; and letters dated April 5, 1983, July 28, 1983, August 17, 1983, and September 22, 1983; application dated June 5, 1984 and letter dated July 16, 1984. The Nuclear Regulatory Commission's regulations shall govern the licensee's statements in applications or letters, unless the statements are more restrictive than the regulations.



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date AUG 23 1984

By PAUL R. GUINN
Paul R. Guinn
Region II, Nuclear Materials
Safety Section
101 Marietta Street, Suite 2900
Atlanta, GA 30323